Table 1 Long COVID-19 outpatient demographics and clinical data
Initial infection variable | Outpatients (n = 23) |
|---|---|
Age (yrs), median (IQR) | 61.0 (19.0) |
Male sex, no. (%) | 13 (56.5) |
Diagnostic test: PCR, serology, no. (%) | 23 (100.0) |
Vaccination status at infection, no. (%) | 2 (8.7) |
Hospitalization, no. (%) | |
Ward | 7 (30.4) |
ICU | 1 (4.3) |
Comorbidities, no. (%) | |
Diabetes | 6 (26.1) |
Hypertension | 8 (34.8) |
Coronary artery/heart disease | 2 (8.7) |
Chronic/congestive heart failure | 0 (0.0) |
Chronic kidney disease | 0 (0.0) |
Cancer | 1 (4.3) |
COPD | 0 (0.0) |
Asthma | 4 (17.4) |
Presenting symptoms at infection, no. (%) | |
Fever | 16 (69.6) |
Cough | 18 (78.3) |
Anosmia/ageusia | 14 (60.9) |
Pharyngitis | 9 (39.1) |
Headache | 14 (60.9) |
Confusion/memory | 2 (8.7) |
Myalgias | 13 (56.5) |
Dyspnea | 16 (69.6) |
Chest pain | 8 (34.8) |
Nausea/vomiting/diarrhea | 12 (52.2) |
Interventions at infection, no. (%) | |
Steroids | 7 (30.4) |
Remdesivir | 1 (4.3) |
Tocilizumab | 1 (4.3) |
Long-COVID clinic variables | |
Follow up, days from infection onset, median (IQR) | 98.5 (47.5) |
Lingering symptoms at follow up, no. (%) | |
Respiratory | 16 (69.6) |
Cardiovascular | 6 (26.1) |
Neurology | 9 (39.1) |
Musculoskeletal | 1 (4.3) |
Gastro-Intestinal | 3 (13.0) |
Psychiatric | 1 (4.3) |
Cutaneous | 0 (0.0) |
Balance | 0 (0.0) |
Chest pain | 4 (17.4) |
Concentration | 1 (4.3) |
Cough | 2 (8.7) |
Dyspnea | 16 (69.6) |
Fatigue | 11 (47.8) |
Headache | 2 (8.7) |
Low mood | 1 (4.3) |
Anxiety | 1 (4.3) |
Memory | 7 (30.4) |
Nausea | 1 (4.3) |
Palpitations | 1 (4.3) |
Paresthesia | 1 (4.3) |
Smell/taste | 2 (8.7) |
Word finding | 2 (8.7) |
Non-specific | 11 (47.8) |
Laboratories at follow up, median (IQR) | |
White blood cell count | 7.1 (2.0) |
Neutrophils | 4.5 (1.6) |
Lymphocytes | 2.0 (0.6) |
Hemoglobin | 140.0 (22.5) |
Platelets | 230.0 (59.5) |
C-Reactive Protein (CRP) | 1.8 (3.5) |
Ferritin | 86.5 (133.8) |
Lactate dehydrogenase (LDH) | 201.0 (37.0) |
Alanine aminotransferase (ALT) | 20.0 (10.5) |
Interventions at follow up, no. (%) | |
Pulmicort | 1 (4.3) |
Anticoagulant | 1 (4.3) |
Symbicort | 10 (43.5) |
Ventolin | 3 (13.0) |
Lasix | 1 (4.3) |
Nasal spray | 2 (8.7) |
Oxygen | 2 (8.7) |
Physiotherapy | 5 (21.7) |
None | 8 (34.8) |